Skip to main content
. 2018 Apr;4(2):a002089. doi: 10.1101/mcs.a002089

Figure 4.

Figure 4.

CT scans of the abdomen and pelvis with contrast prior to initiation of an FGFR inhibitor on trial. (A) Axial CT image with oral and intravenous contrast at the level of the mid pelvis shows a 3-cm soft tissue mass with minimal calcifications (red arrow). (B) Coronal reconstructed CT image with oral and intravenous contrast through the anterior abdomen and pelvis shows the 3-cm soft tissue mass with minimal calcifications (red arrow). CT scans of the abdomen and pelvis with contrast obtained during treatment with FGFR inhibitor on trial. (C) Axial CT image with oral and intravenous contrast at the level of the mid pelvis shows no measurable mass. (D) Coronal reconstructed CT image with oral and intravenous contrast through the anterior abdomen and pelvis shows no measurable mass.